Urinary excretion of melatonin and association with breast cancer: Meta-analysis and review of the literature

Breast Care

Volumn 9, Issue 3, 2014, Pages 182-187

  Basler, Michelle ^a,b   Jetter, Alexander ^a   Fink, Daniel ^b   Seifert, Burkhardt ^c   Kullak Ublick, Gerd A ^a   Trojan, Andreas ^a,d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITÄTSSPITAL ZÜRICH   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d KLINIK IM PARK   (Switzerland)

Author keywords

aMT6s; Breast cancer; Melatonin; Meta analysis; Urinary excretion

Indexed keywords

6 HYDROXYMELATONIN O SULFATE; MELATONIN;

BREAST CARCINOGENESIS; CANCER INCIDENCE; CANCER RISK; CASE CONTROL STUDY; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; GENETIC ASSOCIATION; HEREDITY; HORMONE URINE LEVEL; HUMAN; KIDNEY CONCENTRATING CAPACITY; META ANALYSIS (TOPIC); NORMAL VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; URINARY EXCRETION; ARTICLE; BIOLOGICAL ACTIVITY; BREAST CANCER; MEDLINE; META ANALYSIS;

EID: 84904686524     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000363426     Document Type: Review

References (62)

1. Cohen M, Lippman M, Chabner B: Role of pineal gland in aetiology and treatment of breast cancer. Lancet 1978;2:814-816
2. Tamarkin L, Danforth D, Lichter A, et al.: Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. Science 1982;216:1003-1005
3. Bartsch C, Bartsch H, Fuchs U, Lippert TH, Bellmann O, Gupta D: Stage-dependent depression of melatonin in patients with primary breast cancer. Correlation with prolactin, thyroid stimulating hormone, and steroid receptors. Cancer 1989;64:426-433
4. Feychting M, Osterlund B, Ahlbom A: Reduced cancer incidence among the blind. Epidemiology 1998;9:490-494
5. Kliukiene J, Tynes T, Andersen A: Risk of breast cancer among Norwegian women with visual impairment. Br J Cancer 2001;84:397-399
6. Flynn-Evans EE, Stevens RG, Tabandeh H, Schernhammer ES, Lockley SW: Total visual blindness is protective against breast cancer. Cancer Causes Control 2009;20:1753-1756
7. Sánchez-Barceló EJ, Cos S, Mediavilla D, Martínez- Campa C, González A, Alonso-González C: Melatonin- estrogen interactions in breast cancer. J Pineal Res 2005;38:217-222
8. Rato AG, Pedrero JG, Martinez MA, del Rio B, Lazo PS, Ramos S: Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB J 1999;13:857-868
9. Del Río B, García Pedrero JM, Martínez-Campa C, Zuazua P, Lazo PS, Ramos S: Melatonin, an endogenous- specific inhibitor of estrogen receptor alpha via calmodulin. J Biol Chem 2004;279:38294-38302
10. Cos S, González A, Güezmes A, et al.: Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. Int J Cancer 2006;118:274-278
11. Wilson ST, Blask DE, Lemus-Wilson AM: Melatonin augments the sensitivity of MCF-7 human breast cancer cells to tamoxifen in vitro. J Clin Endocrinol Metab 1992;75:669-670
12. Ram PT, Dai J, Yuan L, et al.: Involvement of the mt1 melatonin receptor in human breast cancer. Cancer Lett 2002;179:141-150
13. Russo IH, Russo J: Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia 1998;3:49-61
14. Tamarkin L, Cohen M, Roselle D, Reichert C, Lippman M, Chabner B: Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz( a)anthracene-induced mammary tumors in the rat. Cancer Res 1981;41:4432-4436
15. Hill SM, Cheng C, Yuan L, et al.: Age-related decline in melatonin and its MT1 receptor are associated with decreased sensitivity to melatonin and enhanced mammary tumor growth. Curr Aging Sci 2013;6:125-133
16. Kim C, Kim N, Joo H, et al.: Modulation by melatonin of the cardiotoxic and antitumor activities of adriamycin. J Cardiovasc Pharmacol 2005;46:200-210
17. Grant SG, Melan MA, Latimer JJ, Witt-Enderby PA: Melatonin and breast cancer: Cellular mechanisms, clinical studies and future perspectives. Expert Rev Mol Med 2009;11:e5
18. Straif K, Baan R, Grosse Y, et al.: Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol 2007;8:1065-1066
19. Reiter RJ, Tan DX, Korkmaz A, Erren TC, Piekarski C, Tamura H, Manchester LC: Light at night, chronodisruption, melatonin suppression, and cancer risk: A review. Crit Rev Oncog 2007; 13:303-328
20. Stevens RG, Blask DE, Brainard GC, et al.: Meeting report: The role of environmental lighting and circadian disruption in cancer and other diseases. Environ Health Perspect 2007;115:1357-1362
21. Davis S, Mirick DK, Stevens RG: Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 2001;93:1557-1562
22. Hansen J, Lassen CF: Nested case-control study of night shift work and breast cancer risk among women in the Danish military. Occup Environ Med 2012;69:551-556
23. Menegaux F, Truong T, Anger A, et al.: Night work and breast cancer: A population-based casecontrol study in France (the CECILE study). Int J Cancer 2013;132:924-931
24. Stevens RG, Hansen J, Costa G, et al.: Considerations of circadian impact for defining 'shift work' in cancer studies: IARC Working Group Report. Occup Environ Med 2011;68:154-162
25. Trichopoulos D, Adami HO, Ekbom A, Hsieh CC, Lagiou P: Early life events and conditions and breast cancer risk: From epidemiology to etiology. Int J Cancer 2008;122:481-485
26. Pinheiro SP, Schernhammer ES, Tworoger SS, Michels KB: A prospective study on habitual duration of sleep and incidence of breast cancer in a large cohort of women. Cancer Res 2006;66:5521-5525
27. Verkasalo PK, Lillberg K, Stevens RG, et al.: Sleep duration and breast cancer: A prospective cohort study. Cancer Res 2005;65:9595-9600
28. Patel SR, Ayas NT, Malhotra MR, et al.: A prospective study of sleep duration and mortality risk in women. Sleep 2004;27:440-444
29. Tamakoshi A, Ohno Y, Group JS: Self-reported sleep duration as a predictor of all-cause mortality: Results from the JACC study, Japan. Sleep 2004; 27:51-54
30. Kakizaki M, Kuriyama S, Sone T, et al.: Sleep duration and the risk of breast cancer: The Ohsaki Cohort Study. Br J Cancer 2008;99:1502-1505
31. Wu AH, Wang R, Koh WP, Stanczyk FZ, Lee HP, Yu MC: Sleep duration, melatonin and breast cancer among Chinese women in Singapore. Carcinogenesis 2008;29:1244-1248
32. Costa G, Haus E, Stevens R: Shift work and cancer - considerations on rationale, mechanisms, and epidemiology. Scand J Work Environ Health 2010;36:163-179
33. Pronk A, Ji BT, Shu XO, et al.: Night-shift work and breast cancer risk in a cohort of Chinese women. Am J Epidemiol 2010;171:953-959
34. Aeschbach D, Lockyer BJ, Dijk DJ, Lockley SW, Nuwayser ES, Nichols LD, Czeisler CA: Use of transdermal melatonin delivery to improve sleep maintenance during daytime. Clin Pharmacol Ther 2009;86:378-382
35. Graham C, Cook MR, Kavet R, Sastre A, Smith DK: Prediction of nocturnal plasma melatonin from morning urinary measures. J Pineal Res 1998; 24:230-238
36. Travis RC, Allen NE, Peeters PH, van Noord PA, Key TJ: Reproducibility over 5 years of measurements of 6-sulphatoxymelatonin in urine samples from postmenopausal women. Cancer Epidemiol Biomarkers Prev 2003;12:806-808
37. Benloucif S, Burgess HJ, Klerman EB, et al.: Measuring melatonin in humans. J Clin Sleep Med 2008;4:66-69
38. Arendt J: Melatonin and the Mammalian Pineal Gland. London, Chapman & Hall, 1995
39. Skene DJ, Bojkowski CJ, Currie JE, Wright J, Boulter PS, Arendt J: 6-sulphatoxymelatonin production in breast cancer patients. J Pineal Res 1990;8:269-276
40. Bartsch C, Bartsch H, Karenovics A, Franz H, Peiker G, Mecke D: Nocturnal urinary 6-sulphatoxymelatonin excretion is decreased in primary breast cancer patients compared to age-matched controls and shows negative correlation with tumor- size. J Pineal Res 1997;23:53-58
41. Travis RC, Allen DS, Fentiman IS, Key TJ: Melatonin and breast cancer: A prospective study. J Natl Cancer Inst 2004;96:475-482
42. Schernhammer ES, Hankinson SE: Urinary melatonin levels and breast cancer risk. J Natl Cancer Inst 2005;97:1084-1087
43. Schernhammer ES, Berrino F, Krogh V, et al.: Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2008;100:898-905
44. Schernhammer ES, Hankinson SE: Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses' Health Study cohort. Cancer Epidemiol Biomarkers Prev 2009;18:74-79
45. Schernhammer ES, Berrino F, Krogh V, et al.: Urinary 6- sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: The ORDET cohort. Cancer Epidemiol Biomarkers Prev 2010;19:729-737
46. Davis S, Mirick DK, Chen C, Stanczyk FZ: Night shift work and hormone levels in women. Cancer Epidemiol Biomarkers Prev 2012;21:609-618
47. Wu AH, Stanczyk FZ, Wang R, Koh WP, Yuan JM, Yu MC: Sleep duration, spot urinary 6-sulfatoxymelatonin levels and risk of breast cancer among Chinese women in Singapore. Int J Cancer 2013;132:891-896
48. Held L, Rufibach K, Burkhardt S: Einführung in die Biostatistik, 4th ed. University of Zurich, 2009
49. Coon SL, Roseboom PH, Baler R, et al.: Pineal serotonin N-acetyltransferase: Expression cloning and molecular analysis. Science 1995;270:1681-1683
50. Klein DC, Coon SL, Roseboom PH, et al.: The melatonin rhythm-generating enzyme: Molecular regulation of serotonin N-acetyltransferase in the pineal gland. Recent Prog Horm Res 1997;52:307- 357; discussion 357-308
51. Deming SL, Lu W, Beeghly-Fadiel A, et al.: Melatonin pathway genes and breast cancer risk among Chinese women. Breast Cancer Res Treat 2012; 132:693-699
52. Bhatti P, Mirick DK, Davis S: Racial differences in the association between night shift work and melatonin levels among women. Am J Epidemiol 2013; 177:388-393
53. Nagata C, Nagao Y, Shibuya C, Kashiki Y, Shimizu H: Association of vegetable intake with urinary 6-sulfatoxymelatonin level. Cancer Epidemiol Biomarkers Prev 2005;14:1333-1335
54. McPherson K, Steel CM, Dixon JM: ABC of breast diseases. Breast cancer - epidemiology, risk factors, and genetics. BMJ 2000;321:624-628
55. Barni S, Lissoni P, Sormani A, et al.: The pineal gland and breast cancer: Serum levels of melatonin in patients with mammary tumors and their rela- Tion to clinical characteristics. Int J Biol Markers 1989;4:157-162
56. Lissoni P, Viviani S, Bajetta E, Buzzoni R, Barreca A, Mauri R, et al.: A clinical study of the pineal gland activity in oncologic patients. Cancer 1986;57:837-842
57. Touitou Y, Fevre-Montange M, Proust J, Klinger E, Nakache JP: Age- and sex-associated modification of plasma melatonin concentrations in man. Relationship to pathology, malignant or not, and autopsy findings. Acta Endocrinol (Copenh) 1985;108:135- 144
58. Hardeland R: Investigational melatonin receptor agonists. Expert Opin Investig Drugs 2010;19:747-764
59. Fung BK: Transducin: Structure, function and role in phototransduction. Progress in Retinal Research 1987;6:151-177
60. Sanchez-Barcelo EJ, Mediavilla MD, Alonso-Gonzalez C, Reiter RJ: Melatonin uses in oncology: Breast cancer prevention and reduction of the side effects of chemotherapy and radiation. Expert Opin Investig Drugs 2012;21:819-831
61. Blask DE, Brainard GC, Dauchy RT, et al.: Melatonin- depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res 2005;65:11174-11184
62. Sigurdardottir LG, Valdimarsdottir UA, Fall K, Rider JR, Lockley SW, Schernhammer E, et al.: Circadian disruption, sleep loss, and prostate cancer risk: A systematic review of epidemiologic studies. Cancer Epidemiol Biomarkers Prev 2012; 21:1002-1011.